Indivior Pharmaceuticals earnings release, August 3, 2026

Indivior Pharmaceuticals, Inc. (INDV) · Form 8-K, Item 2.02 · Filed · SEC filing

Indivior Reports Second Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance

• Q2’26 Total Net Revenue of $343 Million, Up 14% YoY

• Record Quarterly Total SUBLOCADE®

Net Revenue of $253

Million in Q2’26, Up 21% YoY

• Record Quarterly GAAP Net Income of $122 Million and Record

Non-GAAP

Net Income of $142 Million in Q2’26

• Record Quarterly

Adjusted EBITDA of $186 Million in Q2’26, Up 111% YoY

• Repurchased Approximately 4.7 Million Shares in Q2’26 for $175 Million

Richmond, VA, August 3, 2026 – Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today reported its financial results for the second quarter ended June 30, 2026, and raised its full-year 2026 financial guidance.

“Exceptional operational execution in Phase II – Accelerate – of the Indivior Action Agenda fueled strong SUBLOCADE performance in the quarter and is the primary driver of our raised 2026 guidance,” said Joe Ciaffoni, Chief Executive Officer.

“We remain focused on Phase II – Accelerate – for the remainder of 2026 and look forward to closing our proposed merger with Supernus, which is expected in the fourth quarter. Upon the close of our proposed merger, all three Phases of the Indivior Action Agenda will have been successfully completed.”

“We delivered record SUBLOCADE net revenue and adjusted EBITDA in the quarter leading us to raise our 2026 guidance,” said Ryan Preblick, Chief Financial Officer. “We now expect 2026 total SUBLOCADE net revenue growth of 20% year-over-year and adjusted EBITDA growth of 68% year-over-year at the midpoint of our guidance ranges. We returned capital to our shareholders through the repurchase of $175 million in shares during the quarter. We are committed to creating long-term shareholder value.”

Q2 2026 Business Highlights

:

Raising Full-Year 2026 Financial Guidance

:

Full-year financial guidance assumes no material change in exchange rates for key currencies compared with 2025 average rates, notably USD/GBP and

USD/EUR.¹

Financial Results for Quarter Ended June 30, 2026

:

Financial Results for Six Months Ended June 30, 2026

:

Conference Call and Webcast Details

:

As a result of the transaction announcement today, Indivior will host a joint transaction conference call with Supernus in lieu of its previously scheduled second quarter 2026 earnings conference call.

A live webcast will be available here or from the Investor

Relations section of both companies’ website at

Supernus Events & Presentations and www.indivior.com.

Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

A replay of the webcast will be available following the event.

An investor presentation, which will be referenced during the webcast, is also available from the Investor Relations section of both companies’ websites.²

About Indivior

As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, we have revolutionized the science of addiction medicine — developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, we are ushering in a new era, renewing our commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together – with science, people living with OUD, public health champions, and communities, we are powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior.

Columns and rows within financial tables may not foot due to rounding. Percentages and per share data in the financial tables have been calculated using actual, non-rounded figures.

Non-GAAP

Financial Measures

:

Non-GAAP financial measures adjust for non-recurring items and other items representing expenses or income that we believe do not reflect the Company’s ongoing operations or the adjustment of which may help with the comparison to prior periods. The Company believes its non-GAAP financial measures may be useful to investors to understand the Company’s performance. In addition, the Company uses “Adjusted EBITDA” in its annual incentive plan in which all executive officers participate.

Financial statements

Income Statement

Three Months Ended June 30, — Condensed consolidated statements of operations (in millions)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net revenue343302660568
Cost of sales50529096
Gross profit294250570472
Selling, general and administrative122158245291
Research and development12212843
Total operating expenses134179273334
Operating income16072297138
Interest (income)-3-6-5-10
Interest expense215927
Loss on debt extinguishment18
Income before income taxes16062276121
Income tax expense38446556
Net income1221821165
Earnings per shareBasic1.020.151.730.53
Earnings per shareDiluted0.980.141.670.52

Income Statement

Three Months Ended June 30, — Selected revenue information (in millions)

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
US:SUBLOCADE*238195455359
US:Sublingual & other5752107107
US:PERSERIS1581012
US:Total U.S.300256572478
US:Rest of World43468890
US:Net revenue343302660568
US:*Total SUBLOCADE net revenue253209486385

Income Statement

Three Months Ended June 30, — diluted earnings per share, is included in the table below.

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
GAAP net income1221821165
Adjustments in cost of sales14252
Adjustments in operating expenses22124520
Adjustments in interest expense44
Loss on debt extinguishment18
Adjustments in tax expenses-528-1429
Non-GAAP net income14264266121
Shares used in computing diluted non-GAAP earnings per share124126127125
Non-GAAP diluted earnings per share1.150.512.10.96

Income Statement

Three Months Ended June 30,

Three Months Ended June 30, – 2026Three Months Ended June 30, – 2025Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Net income1221821165
Interest (income)-3-6-5-10
Interest expense215927
Income tax expense38446556
Depreciation and amortization2345
Stock-based compensation1182014
Corporate initiative transition114265
Manufacturing transition2242
Loss on debt extinguishment18
Litigation settlement expense1
Adjusted EBITDA18688350165

Balance Sheet

June 30, 2026 — Condensed consolidated balance sheets (in millions)

June 30, 2026December 31, 2025
Current assetsCash and cash equivalents222195
Current assetsAccounts receivable, net of allowances of $3 (2026) and $4 (2025)271253
Current assetsInventories150153
Current assetsPrepaid expenses1434
Current assetsCurrent tax receivable162
Current assetsOther current assets5416
Current assetsTotal current assets725652
Current assetsLong-term investments2728
Current assetsProperty, plant and equipment, net162144
Current assetsOperating lease right of use assets, net2126
Current assetsGoodwill and other intangible assets, net22
Current assetsDeferred tax assets271323
Current assetsOther noncurrent assets2427
Current assetsTotal assets1,2331,201
Current liabilitiesAccrued rebates and product returns610582
Current liabilitiesAccounts payable and accrued expenses206250
Current liabilitiesAccrued litigation settlement expenses, current1442
Current liabilitiesCurrent portion of long-term debt29
Current liabilitiesOperating lease liabilities, current910
Current liabilitiesIncome taxes payable302
Current liabilitiesTotal current liabilities868914
Current liabilitiesLong-term debt, less current portion487290
Current liabilitiesAccrued litigation settlement expenses, noncurrent4252
Current liabilitiesOperating lease liabilities, noncurrent1322
Current liabilitiesOther noncurrent liabilities3121
Current liabilitiesTotal liabilities1,4411,300
Stockholders’ deficitCommon stock, par value $0.001 per share (2026) and $0.50 per share (2025) Issued shares: 118 (2026) and 125 (2025)62
Stockholders’ deficitAdditional paid-in capital155112
Stockholders’ deficitAccumulated other comprehensive loss-28-30
Stockholders’ deficitAccumulated deficit-334-243
Stockholders’ deficitTotal stockholders’ deficit-208-98
Stockholders’ deficitTotal liabilities and stockholders’ deficit1,2331,201

Cash Flow

Six Months Ended June 30, — Condensed consolidated statements of cash flows (in millions)

Six Months Ended June 30, – 2026Six Months Ended June 30, – 2025
Cash flows from operating activities:Net income21165
Adjustments to reconcile net income to net cash from operating activities:Depreciation and amortization45
Adjustments to reconcile net income to net cash from operating activities:Amortization of right-of-use assets35
Adjustments to reconcile net income to net cash from operating activities:Stock-based compensation expense2014
Adjustments to reconcile net income to net cash from operating activities:Impairment of tangible and intangible assets8
Adjustments to reconcile net income to net cash from operating activities:Loss on debt extinguishment18
Full release

Important Cautionary Note Regarding Forward-Looking Statements

:

This announcement contains certain statements that are forward-looking statements. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements include, among other things, express and implied statements regarding: our 2026 financial guidance including with respect to net revenue, total SUBLOCADE net revenue, non-GAAP operating expenses, and adjusted EBITDA; potential business development opportunities to acquire the next commercial stage growth drivers; potential expense reductions; expected acceleration in

SUBLOCADE net revenue and dispense unit growth; expected growth in adjusted EBITDA, cash flow, and our bottom line, and expected acceleration of such growth; potential future share repurchases; expected creation of shareholder value; anticipated benefits of the proposed merger with Supernus, the expected timing of completion of the proposed merger, estimated costs associated with the proposed merger, and other statements containing the words “believe,” “anticipate,”

“plan,” “expect,” “intend,” “estimate,” “forecast,” “strategy,” “target,” “guidance,” “outlook,” “potential,”... (truncated)” “would,” “could,” “can,” the negatives thereof, and variations thereon and similar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future.

Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and only express management’s beliefs regarding future results or events which, by their nature, are inherently uncertain and outside of management’s control or ability to predict. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of factors, including but not limited to: lower than expected future sales of our products; greater than expected impacts from competition; and unanticipated costs including the effects of potential tariffs and potential retaliatory tariffs; market conditions; the decisions of third parties outside of our control with respect to potential business development opportunities; the risk that the proposed merger with Supernus may not be completed on the anticipated timeline or at all; the failure to obtain required stockholder or regulatory approvals for the merger, or the imposition of conditions in connection with such approvals; the restrictions during the pendency of the transaction that may limit the parties’ ability to pursue business opportunities or strategic transactions; the risk that the anticipated benefits, synergies, growth, profitability, cash flow generation and earnings accretion of the merger are not realized or are realized more slowly than expected; and the difficulties, costs and risks relating to the integration of the two businesses. For additional information about some of the risks and important factors that could affect our future results and financial condition, see “Important Cautionary Note Regarding Forward-looking Statements” and “Risk Factors” in Indivior’s Annual Report on Form

10-K filed February 26, 2026, and our other filings with the U.S. Securities and Exchange Commission.

We have based the forward-looking statements in this report on our current expectations and beliefs concerning future events. Forward-looking statements contained in this report speak only as of the day they are made and, except as required by law, we undertake no obligation to update or revise any forward-looking statement, whether due to new information, or to reflect events or developments that occur after the date the statement was made.³

Important Additional Information and Where to Find It

In connection with the proposed transaction, Indivior intends to file with the SEC a registration statement on Form

S-4, which will include a document that serves as a prospectus of Indivior and a joint proxy statement of Indivior and Supernus (the “joint proxy statement/prospectus”). Each party also plans to file other relevant documents with the SEC regarding the proposed transaction. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE

THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. A definitive joint proxy statement/prospectus will be sent to Indivior’s stockholders and Supernus’ stockholders. Investors and securityholders may obtain a free copy of the joint proxy statement/prospectus (if and when it becomes available) and other relevant documents filed by Indivior and Supernus with the SEC at the SEC’s website at www.sec.gov. Copies of the documents filed by Indivior with the SEC will be available free of charge on Indivior’s website at www.indivior.com or by contacting Indivior’s Investor Relations at

InvestorRelations@indivior.com. Copies of the documents filed by Supernus with the SEC will be available free of charge on Supernus’ website at www.supernus.com.

No Offer or Solicitation

This communication is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy or exchange any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. This communication does not constitute a prospectus or prospectus equivalent document. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Participants in the Solicitation

Indivior and Supernus and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information about directors and executive officers of Indivior is available in the Indivior proxy statement for its 2026 Annual Meeting, which was filed with the SEC on March 27,

2026. Information about directors and executive officers of Supernus is available in the Supernus proxy statement for its 2026 Annual Meeting, which was filed with the SEC on April 30, 2026. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials filed with the SEC regarding the proposed transaction when they become available. Investors should read the joint proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. Investors may obtain free copies of these documents from

Indivior and Supernus as indicated above.

For Further Information⁴

Indivior Pharmaceuticals, Inc.... (truncated)s)

(Unaudited)

Condensed consolidated statements of operations⁵

Indivior Pharmaceuticals, Inc.

(Amounts in millions, except per share data and percentages)

(Unaudited)

Condensed consolidated balance sheets⁶

Indivior Pharmaceuticals, Inc.

(Amounts in millions, except per share data and percentages)

(Unaudited)

Condensed consolidated statements of cash flows⁷

Indivior Pharmaceuticals, Inc.

(Amounts in millions, except per share data and percentages)

(Unaudited)

Selected revenue information

Reconciliation of GAAP to non-GAAP financial information

Non-GAAP diluted earnings per share

Management believes that non-GAAP diluted earnings per share, which excludes the impact of certain non-recurring items and other adjustments, net of applicable tax effects, may provide useful information to shareholders regarding underlying trends in earnings per share. A reconciliation of GAAP net income to non-GAAP net income, as well as the weighted average shares used in computing non-GAAP diluted earnings per share, is included in the table below.⁸

Indivior Pharmaceuticals, Inc.

(Amounts in millions, except per share data and percentages)

(Unaudited)

Adjusted EBITDA

Adjusted EBITDA is a non-GAAP financial measure that represents GAAP net income adjusted to exclude interest expense, interest income, income tax expense or benefit, depreciation and amortization, stock-based compensation, and other adjustments reflecting changes in our business that do not represent ongoing operations. Adjusted EBITDA, as used by us, may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.⁹

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Indivior Pharmaceuticals earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.